deltatrials
Completed EARLY_PHASE1 INTERVENTIONAL 2-arm NCT03618654

Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma

Window of Opportunity for Durvalumab (MEDI4736) Plus Metformin Trial of in Squamous Cell Carcinoma of the Head and Neck

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Conditions Head and Neck Squamous Cell Carcinoma Oral Cavity Squamous Cell Carcinoma Oropharyngeal Squamous Cell Carcinoma
Interventions Durvalumab Metformin
Updated 15 times since 2018 Last updated: May 14, 2025 Started: Nov 1, 2018 Primary completion: Nov 20, 2021 Completion: Dec 7, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This EARLY_PHASE1 trial investigates Head and Neck Squamous Cell Carcinoma and Oral Cavity Squamous Cell Carcinoma and is currently completed. Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University leads this study, which shows 15 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Sep 2018 – ~Dec 2018 · 3 months · monthly snapshot~Dec 2018 – ~Feb 2019 · 2 months · monthly snapshot~Feb 2019 – ~Aug 2019 · 6 months · monthly snapshot~Aug 2019 – ~Nov 2019 · 3 months · monthly snapshot~Nov 2019 – ~Jan 2020 · 2 months · monthly snapshot~Jan 2020 – ~Jan 2021 · 12 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Sep 2022 · 11 months · monthly snapshot~Sep 2022 – ~Apr 2024 · 19 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jun 2025 · 9 months · monthly snapshot~Jun 2025 – ~Feb 2026 · 8 months · monthly snapshot~Feb 2026 – present · 6 months · monthly snapshot

Change History

15 versions recorded

  1. Feb 2026 — Present [monthly]

    Completed EARLY_PHASE1

  2. Jun 2025 — Feb 2026 [monthly]

    Completed EARLY_PHASE1

  3. Sep 2024 — Jun 2025 [monthly]

    Completed EARLY_PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Completed EARLY_PHASE1

  5. Apr 2024 — Jul 2024 [monthly]

    Completed EARLY_PHASE1

    Status: Active Not Recruiting → Completed · Phase: PHASE1 → EARLY_PHASE1

▶ Show 10 earlier versions

  1. Sep 2022 — Apr 2024 [monthly]

    Active Not Recruiting PHASE1

  2. Oct 2021 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1

  3. Sep 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  4. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

  5. Jan 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  6. Nov 2019 — Jan 2020 [monthly]

    Recruiting PHASE1

  7. Aug 2019 — Nov 2019 [monthly]

    Recruiting PHASE1

  8. Feb 2019 — Aug 2019 [monthly]

    Recruiting PHASE1

    Status: Active Not Recruiting → Recruiting

  9. Dec 2018 — Feb 2019 [monthly]

    Active Not Recruiting PHASE1

    Status: Not Yet Recruiting → Active Not Recruiting

  10. Sep 2018 — Dec 2018 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Data source: Thomas Jefferson University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations